Form 4: Phreesia Inc. Executive David Linetsky Reports Acquisition of Restricted Stock Units

David Linetsky, SVP of Life Sciences at Phreesia, Inc., reports the acquisition of 2,000 Restricted Stock Units (RSUs) under the company's 2019 Stock Option and Incentive Plan.

Summary

• On August 15, 2024, David Linetsky, SVP of Life Sciences at Phreesia, Inc., acquired 2,000 Restricted Stock Units (RSUs).
• These RSUs were issued under the company's 2019 Stock Option and Incentive Plan.
• Each RSU represents the contingent right to receive one share of Phreesia's common stock.
• The RSUs vest over four years: 10% on August 15, 2025, 20% on August 15, 2026, 30% on August 15, 2027, and 40% on August 15, 2028, contingent upon continued service to Phreesia.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The grant of RSUs aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The vesting schedule of the RSUs suggests an expectation of continued service and contribution from the executive over the next four years.

Industry Context

Grants of restricted stock units are a common practice in the technology and healthcare industries to incentivize and retain key executives.

Comparison to Industry Standards

• Companies like Veeva Systems and Allscripts also use equity-based compensation, including RSUs, to align executive incentives with shareholder value.
• The vesting schedule is fairly standard, with back-ended vesting to encourage long-term commitment, similar to plans at Cerner and athenahealth.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning executive interests with company performance.
• Employees may see this as a sign of stability and investment in leadership.

Key Dates